Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia

Cancer

Volumn 119, Issue 22, 2013, Pages 4036-4043

  O'Hear, Carol ^a,b   Inaba, Hiroto ^a,b   Pounds, Stanley ^a   Shi, Lei ^a   Dahl, Gary ^c   Paul Bowman, W ^d   Taub, Jeffrey W ^e   Pui, Ching Hon ^a,b   Ribeiro, Raul C ^a,b   Coustan Smith, Elaine ^f   Campana, Dario ^f   Rubnitz, Jeffrey E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^d Stanford Cancer Center ^*  (United States)

^e CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

acute myeloid leukemia; gemtuzumab ozogamicin; minimal residual disease; treatment related mortality

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; EVENT FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LOW DRUG DOSE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL;

ACUTE MYELOID LEUKEMIA; GEMTUZUMAB OZOGAMICIN; MINIMAL RESIDUAL DISEASE; TREATMENT-RELATED MORTALITY;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM, RESIDUAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84887079391     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28334     Document Type: Article

References (38)

1. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009; 27: 4007-4013.
2. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol. 2010; 11: 543-552.
3. Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011; 155: 366-376.
4. Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011; 29: 310-315.
5. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 2012; 118: 761-769.
6. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: Results of AML-BFM 98. J Clin Oncol. 2006; 24: 4499-4506.
7. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982; 60: 454-462.
8. Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: Results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001; 15: 348-354.
9. O'Brien TA, Russell SJ, Vowels MR, et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. Blood. 2002; 100: 2708-2716.
10. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol. 2010; 28: 586-595.
11. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009; 361: 1249-1259.
12. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009; 361: 1235-1248.
13. Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011; 117: 2358-2365.
14. Wells RJ, Woods WG, Lampkin BC, et al. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. J Clin Oncol. 1993; 11: 538-545.
15. Stevens RF, Hann IM, Wheatley K, Gray RG,. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: Results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol. 1998; 101: 130-140.
16. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001; 19: 3244-3254.
17. Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood. 2005; 106: 1183-1188.
18. Zwaan CM, Reinhardt D, Zimmerman M, et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: Results of a phase II study. Br J Haematol. 2010; 148: 768-776.
19. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001; 7: 1490-1496.
20. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001; 92: 406-413.
21. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003; 102: 1578-1582.
22. Aplenc R, Alonzo TA, Gerbing RB, et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2008; 26: 2390-3295.
23. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003; 102: 4277-4283.
24. Brethon B, Yakouben K, Oudot C, et al. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol. 2008; 143: 541-547.
25. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J Clin Oncol. 2011; 29: 369-377.
26. Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012; 379: 1508-1516.
27. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012; 30: 3924-3931.
28. Ravandi F, Kantarjian H,. Haematological cancer: gemtuzumab ozogamicin in acute myeloid leukaemia. Nat Rev Clin Oncol. 2012; 9: 310-311.
29. Estey E,. Treatment of AML: resurrection for gemtuzumab ozogamicin? Lancet. 2012; 379: 1468-1469.
30. Inaba H, Coustan-Smith E, Cao X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol. 2012; 30: 3625-3632.
31. Kaplan EL, Meier P,. Non-parametric estimation for incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
32. Campana D, Leung W,. Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol. 2013; 162: 147-161.
33. Lamba JK, Pounds S, Cao X, et al. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. Leukemia. 2009; 23: 402-404.
34. Mortland L, Alonzo TA, Walter RB, et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013; 19: 1620-1627.
35. Hasle H, Abrahamsson J, Forestier E, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: Results from NOPHO-AML 2004. Blood. 2012; 120: 978-984.
36. Walter RB, Appelbaum FR, Estey EH, Bernstein ID,. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012; 119: 6198-6208.
37. Arndt C, von BM, Cartellieri, M, et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia. 2013; 27: 964-967.
38. Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia. 2013; 27: 1107-1115.